Daily Sepsis Research Analysis
Analyzed 40 papers and selected 3 impactful papers.
Summary
Today’s most impactful sepsis research spans mechanistic, translational, and clinically actionable advances. MMP8 was identified as a mediator of pulmonary vascular leakage through ERK-dependent VE-cadherin disruption, while portal delivery of budesonide preserved bacterial clearance in experimental abdominal sepsis. A large pediatric study further showed that CRP responses are markedly attenuated in newborns and neonates despite greater illness severity, challenging the use of uniform age-independent CRP thresholds.
Research Themes
- MMP8-mediated endothelial barrier failure as a therapeutic target in sepsis
- Hepatic-targeted glucocorticoid delivery and preservation of bacterial clearance
- Age-dependent interpretation of CRP in pediatric sepsis
Selected Articles
1. MMP8 exacerbates sepsis-induced pulmonary vascular leakage by disruption of endothelial VE-cadherin through ERK signalling.
This multimodal study identified MMP8 as an active mediator of sepsis-induced pulmonary endothelial hyperpermeability rather than merely a disease-associated biomarker. MMP8 interacted with ERK, activated calpains, and promoted VE-cadherin proteolysis and internalization; pharmacologic inhibition reduced vascular leakage, organ injury, and mortality in septic mice.
Impact: The study connects a clinically observed biomarker with a defined endothelial injury mechanism and provides in vivo evidence for therapeutic inhibition. This creates a mechanistically grounded route toward biomarker-guided treatment of sepsis-associated pulmonary vascular leakage.
Clinical Implications: Serum MMP8 may help identify septic patients at risk of pulmonary vascular leakage, particularly pleural effusion, but clinical use requires prospective validation. MMP8 or downstream ERK-calpain-VE-cadherin signaling may represent candidate therapeutic targets.
Key Findings
- MMP8 expression increased in LPS-treated endothelial cells and in lung tissue from mice with cecum ligation and puncture-induced sepsis.
- MMP8 promoted ERK phosphorylation, calpain activation, VE-cadherin proteolysis, and clathrin- and caveolin-1-mediated VE-cadherin internalization.
- Pharmacologic MMP8 inhibition reduced pulmonary vascular leakage, multi-organ injury, and mortality in septic mice; serum MMP8 was elevated in patients with sepsis and was highest in those with pleural effusion.
Methodological Strengths
- Integrated loss-of-function and gain-of-function experiments in endothelial cells with in vivo validation in a cecum ligation and puncture sepsis model.
- Mechanistic linkage among MMP8, ERK signaling, calpain activation, and VE-cadherin barrier disruption, supplemented by clinical biomarker observations.
Limitations
- The therapeutic findings were primarily generated in experimental models and may not translate directly to human sepsis.
- The clinical biomarker and nomogram findings require validation in larger, prospective, multicenter cohorts before clinical implementation.
Future Directions: Future work should evaluate selective MMP8 inhibition, define treatment windows and safety profiles, and validate serum MMP8 thresholds against pulmonary vascular leakage, acute respiratory distress syndrome, and mortality in prospective cohorts.
Endothelial dysfunction is a major contributor to multi-organ failure and mortality in sepsis, with the lungs being particularly susceptible to vascular leakage. Previous studies have implicated matrix metalloproteinase 8 (MMP8) in sepsis pathogenesis. However, the role of MMP8 in maintaining endothelial barrier integrity during sepsis remains unclear. This study aimed to investigate the role of MMP8 in sepsis-induced vascular leakage and the underlying mechanisms. A significant increase in MMP8 expression was observed in LPS-treated endothelial cells and lung tissues from mice with cecum ligation and puncture-induced sepsis.
2. Impact of Regional Hepatic Immunosuppression With Budesonide on Bacterial Elimination in Porcine Abdominal Sepsis.
In a controlled porcine model of gram-negative abdominal sepsis, portal venous budesonide did not impair hepatic bacterial or endotoxin elimination and produced a stronger early anti-inflammatory response than systemic administration. Systemic budesonide was associated with higher arterial and hepatic venous bacterial counts, suggesting that hepatic-targeted delivery may improve the therapeutic balance of glucocorticoids.
Impact: The study challenges the assumption that glucocorticoid exposure has uniform effects across organs and demonstrates that route of delivery can determine bacterial-clearance risk. It provides a novel translational strategy for separating hepatic anti-inflammatory effects from systemic immunosuppression.
Clinical Implications: The findings do not support immediate clinical use of portal budesonide, but they justify investigation of liver-targeted or locally delivered corticosteroid strategies in sepsis. Any clinical translation would require confirmation of safety, pharmacokinetics, infection control, and effects on organ failure in humans.
Key Findings
- Portal and systemic budesonide produced no significant difference in hepatic or portal venous bacterial-count ratios or endotoxin elimination.
- Arterial and hepatic venous bacterial counts were higher after systemic budesonide than after portal administration.
- Portal budesonide increased early IL-10 and reduced IL-6 compared with systemic administration or septic controls, indicating a more favorable early anti-inflammatory profile.
Methodological Strengths
- The large-animal porcine model closely reflects clinically relevant portal and systemic circulation physiology.
- The study directly compared portal delivery, systemic delivery, and septic controls while measuring bacterial counts across multiple vascular compartments and inflammatory mediators.
Limitations
- The sample size was small, with eight animals in each septic treatment group and three non-septic controls.
- The model used short-term experimental E. coli infusion and may not reproduce the heterogeneous sources, timing, and chronicity of human sepsis.
Future Directions: Further studies should test liver-targeted steroid delivery in polymicrobial sepsis, evaluate dose-response and longer-term outcomes, and develop clinically feasible delivery systems that preserve bacterial clearance while controlling excessive inflammation.
INTRODUCTION: The liver is essential for bacterial elimination, preventing intestinal bacteria from entering the systemic circulation, and for producing inflammatory cytokines. Glucocorticoids have been reported to exert heterogeneous effects on bacterial clearance in sepsis. Using a porcine model of gram-negative abdominal sepsis, we investigated how portal venous administration of budesonide, a glucocorticoid with extensive hepatic first-pass metabolism, affects hepatic bacterial and endotoxin elimination as well as the systemic inflammatory response, in comparison with systemic administration and no treatment.
3. Attenuated C-reactive protein response to infection in newborns and neonates: an age-stratified analysis in children with sepsis.
Among 1,228 children with sepsis, newborns and neonates had the greatest illness severity but the lowest median CRP concentrations. Older children had substantially higher CRP levels despite lower severity, demonstrating that a uniform CRP threshold can underestimate serious infection in the youngest patients.
Impact: This study addresses a common and potentially dangerous diagnostic assumption in pediatric sepsis: that CRP magnitude has the same meaning across ages. Its large age-stratified cohort provides clinically relevant evidence for age-specific interpretation of a widely used biomarker.
Clinical Implications: Low or modest CRP elevation should not reassure clinicians when newborns or neonates have clinical features of sepsis. Antibiotic decisions and risk assessment should integrate age-specific CRP interpretation with clinical examination, hemodynamics, microbiology, and other biomarkers such as procalcitonin.
Key Findings
- The study included 1,228 children with sepsis stratified into newborn, neonate, infant, toddler/preschool, and school-age/adolescent groups.
- Newborns and neonates had the highest severity indicators but the lowest median CRP levels: 2.32 mg/L and 5.09 mg/L, respectively.
- Older children had 5- to 10-fold higher CRP levels despite substantially lower clinical severity, indicating that a single CRP cutoff is inappropriate across pediatric ages.
Methodological Strengths
- The cohort was relatively large for a pediatric sepsis study and used clinically meaningful age strata based on international pediatric sepsis recommendations.
- The analysis compared biomarker levels with severity indicators across multiple developmental stages, revealing a clinically important discordance.
Limitations
- The single-center retrospective cross-sectional design limits generalizability and cannot establish causal mechanisms for attenuated CRP responses.
- The abstract does not provide detailed information on pathogen distribution, timing of CRP sampling, or adjustment for prematurity and other potential confounders.
Future Directions: Prospective multicenter studies should establish age-specific CRP reference ranges and evaluate integrated diagnostic algorithms combining CRP, procalcitonin, clinical findings, and serial measurements in newborns and neonates.
PURPOSE: C-reactive protein (CRP) is widely used to guide antibiotic therapy in children; however, a uniform CRP cut-off is commonly applied across all pediatric age groups. This study aimed to investigate whether the CRP response to infection differs by age in children with sepsis. METHODS: This single-center retrospective cross-sectional study included children with a discharge diagnosis of sepsis. Patients were stratified into five age groups according to the recommendations of the International Pediatric Sepsis Consensus Conference: newborn (0 < age ≤ 7 days), neonate (7 < age ≤ 30 days), infant (30 days < age ≤ 2 years), toddler/preschool (2 < age ≤ 6 years), and school age/adolescent (6 < age < 18 years).